Pre-Clinical Testing of Real-Time PCR Assays for Diarrheal Disease Agents of Genera Escherichia and Shigella
Abstract
Pre-clinical test results qualify ETEC and Shigella real-time PCR assays as lead candidates for transition to clinical phase testing. Diagnostic sensitivity results were 96% to 100% in testing conducted under laboratory and field conditions. Current commercially available molecular-based diagnostic assay sensitivity is 95% to 98% representing the standard that must be met or exceeded to qualify as a candidate for FDA clearance. In addition to test activities, Enterotoxigenic Escherichia coli Detection Kit and Shigella Detection Kit pre-IDE documents were prepared to serve as a point of departure for discussion with the FDA Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD) on guidance and clarification of specific testing requirements for eventual clearance. During the conduct of RDT&E activities a formal GME training program was established by the investigators. The program provides for scholarly and challenging research opportunities in a real-world environment. Under this project, an Air Force resident physician completed research which directly resulted in advancing Force Health Protection diarrheal disease diagnostic technologies toward clearance. Two separate research projects were completed, abstracts prepared, and posters presented at a medical symposium. The resident successfully completed WHAMC Pathology Department Research Elective 144. These projects are described in the Results section. Project activities are provided in Appendix A and course description and requirements are provided in Appendix B.
Document Details
- Document Type
- Technical Report
- Publication Date
- May 16, 2014
- Accession Number
- ADA600976
Entities
People
- Carl J. Mason
- James C. Mcavin
Organizations
- 59th Medical Wing